FDA: Cyramza approval now includes non-small-cell lung CA

FDA: cyramza approval now includes non-small-cell lung CA

(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs.

Cyramza was first approved in April to treat advanced or (GEJ) adenocarcinoma, and approval was widened in November to include advanced gastric or GEJ adenocarcinoma in combination with paclitaxel.

Clinical side effects have included neutropenia, stomatitis, fatigue, severe bleeding, blood clots, raised blood pressure, and impaired wound healing.

Cyramza is marketed by Eli Lilly, based in Indianapolis.

Explore further

Cyramza approved for stomach cancer

More information: More Information

Health News Copyright © 2014 HealthDay. All rights reserved.

Citation: FDA: Cyramza approval now includes non-small-cell lung CA (2014, December 14) retrieved 23 June 2021 from https://medicalxpress.com/news/2014-12-fda-cyramza-non-small-cell-lung-ca.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments